Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies

Journal of Infection and Chemotherapy

Volumn 18, Issue 6, 2012, Pages 793-806

  Tasaka, Sadatomo ^a   Tokuda, Hitoshi ^b  

^a KEIO UNIVERSITY   (Japan)

^b Social Insurance Central General Hospital   (Japan)

Author keywords

Non HIV infected patients; PCR; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis; d Glucan

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BELATACEPT; BETA GLUCAN; BLEOMYCIN; CALCINEURIN INHIBITOR; CLINDAMYCIN; CORTICOSTEROID; DASATINIB; ETANERCEPT; FLUDARABINE; INFLIXIMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; PENTAMIDINE; PREDNISONE; PRIMAQUINE; PURINE DERIVATIVE; RITUXIMAB; SULFAMETHOXAZOLE; TOCILIZUMAB; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

BONE MARROW DEPRESSION; BREAST CANCER; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ERUPTION; DRUG MEGADOSE; DYSGLYCEMIA; ENTERITIS; FUNGAL COLONIZATION; FUNGUS TRANSMISSION; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LEUKEMIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYMERASE CHAIN REACTION; POLYMYOSITIS; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS; COMMUNICABLE DISEASE; IMMUNOCOMPETENCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMOCYSTIS JIROVECI;

COMMUNICABLE DISEASES, EMERGING; HIV INFECTIONS; HUMANS; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE AGENTS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

EID: 84880398399     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0453-0     Document Type: Review

References (117)

1. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301:2578-85.
2. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-98. (Pubitemid 38736546)
3. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5:298-308. (Pubitemid 46443606)
4. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010;24:107-38.
5. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011;24:534-44.
6. Beck JM, Cushion MT. Pneumocystis workshop: 10th anniversary summary. Eukaryot Cell. 2009;8:446-60.
7. Huang L, Morris A, Limper AH, Beck JM. An official ATS workshop summary: recent advances and future directions in Pneumocystis pneumonia. Proc Am Thorac Soc. 2006;3:655-64. (Pubitemid 44788220)
8. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5:41-59.
9. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-71. (Pubitemid 14143939)
10. Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther. 2010;8:683-701.
11. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204-9. (Pubitemid 19276197)
12. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome. Mayo Clin Proc. 1996;71:5-13.
13. Roblot F, Godet C, Le Moal G, Garo B. Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523-31. (Pubitemid 35013591)
14. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6:644-52.
15. FDA arthritis advisory committee. Safety update on TNF-α antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3779b2-01-cber-safety%20-revision2.pdf. (online).
16. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891.
17. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35-41. (Pubitemid 8268789)
18. Peglow SL, Smulian AG, Linke MJ, Pogue CL, Nurre S, Crisler J, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296-306. (Pubitemid 20056662)
19. Huang L, Crothers K, Morris A, Groner G, Fox M, Turner JR, et al. Pneumocystis colonization in HIV-infected patients. J Eukaryot Microbiol. 2003;50(Suppl):616-7. (Pubitemid 38043038)
20. Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS. 1999;13:535-6.
21. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Calderon EJ, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis. 2005;11:245-50. (Pubitemid 40239241)
22. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation. 2009;88:380-5.
23. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197:10-7. (Pubitemid 351263460)
24. Mekinian A, Durand-Joly I, Hatron PY, Moranne O, Denis G, Queyrel V. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology. 2011;50:569-77.
25. Wissmann G, Morilla R, Martín-Garrido I, Friaza V, Respaldiza N, Calderón EJ, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest. 2011;41:343-8.
26. Durand-Joly I, Soula F, Chabé M, Dalle JH, Lafitte JJ, Dei-Cas E, et al. Long-term colonization with Pneumocystis jirovecii in hospital staffs: a challenge to prevent nosocomial pneumocystosis. J Eukaryot Microbiol. 2003;50(Suppl):614-45. (Pubitemid 38043037)
27. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis. 2010;50:347-53.
28. Manoloff ES, Francioli P, Taffé P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis. 2003;9:132-4. (Pubitemid 36110217)
29. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun. 1993;61:5406-9. (Pubitemid 23353929)
30. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002;4:95-103. (Pubitemid 34127996)
31. Helweg-Larsen J, Lee CH, Jin S, Hsueh JY, Benfield TL, Hansen J, et al. Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. AIDS. 2001;15:451-9. (Pubitemid 32207564)
32. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745-7. (Pubitemid 27452401)
33. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009;36:1600-5.
34. Gigliotti F, Wright TW. Immunopathogenesis of Pneumosystis carinii pneumonia. Expert Rev Mol Med. 2005;7:1-16. (Pubitemid 43118222)
35. Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010;5:43-65.
36. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997;99:2110-7. (Pubitemid 27203767)
37. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000;164:3755-63. (Pubitemid 30169832)
38. Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1995;151:1058-62.
39. Tasaka S, Kobayashi S, Kamata H, Kimizuka Y, Fujiwara H, Funatsu Y, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with Pneumocystis pneumonia. Microbiol Immunol. 2010;54:425-33.
40. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am J Pathol. 1990;136:1173-86. (Pubitemid 20188504)
41. Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2010;15:126-31.
42. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25:382-8. (Pubitemid 43885682)
43. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832-7.
44. Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Azoulay E, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305-10. (Pubitemid 47621008)
45. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187-98.
46. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009;39:1098-109.
47. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008;6:122-74. (Pubitemid 351340523)
48. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052-9. (Pubitemid 47357136)
49. Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res. 2005;25:651-5. (Pubitemid 40470077)
50. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med. 1995;155:1125-8.
51. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis. 2007;44:1143-9. (Pubitemid 46651235)
52. Schmoldt S, Schuhegger R, Wendler T, Huber I, Söllner H, Hogardt M, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46:966-71. (Pubitemid 351379988)
53. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2003;5:84-93. (Pubitemid 37221472)
54. De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect. 2010;16:1375-7.
55. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151:795-9.
56. Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du Huong LT, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis. 1995;54:991-4.
57. Tasaka S, Hasegawa N, Yamada W, Saito F, Nishimura T, Ishizaka A. Clinical features of Pneumocystis pneumonia in patients with systemic lupus erythematosus. Nihon Kokyuki Gakkai Zasshi 2006;44:613-619 (in Japanese).
58. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246-51. (Pubitemid 24078834)
59. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780-9. (Pubitemid 29172000)
60. Bachelez H, Schremmer B, Cadranel J, Mouly F, Sarfati C, Agbalika F, et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med. 1997;157:1501-3. (Pubitemid 27300399)
61. Phair J, Munõz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161-5. (Pubitemid 20036389)
62. Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991;46:205-7.
63. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome. A multicenter study. Intern Med. 2008;47:915-23. (Pubitemid 351936186)
64. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
65. Louie GH, Wang Z, Ward MM. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Rheum. 2010;62:3826-7.
66. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305-12.
67. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;6:898-906.
68. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Goto H, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 2011;50:305-13.
69. Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis - a need for prophylaxis. J Crohns Colitis. 2010;4:606-9.
70. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481-4. (Pubitemid 46776482)
71. Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, et al. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. Dig Dis Sci. 2007;52:1438-41. (Pubitemid 46776504)
72. Flori P, Bellete B, Durand F, Raberin H, Cazorla C, Hafid J, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004;53:603-7. (Pubitemid 38932356)
73. Caliendo AM, Hewitt PL, Allega JM, Keen A, Ruoff KL, Ferraro MJ. Performance of a PCR assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol. 1998;36:979-82. (Pubitemid 28146280)
74. Alvarez-Martínez MJ, Miró JM, Valls ME, Moreno A, Rivas PV, Solé M, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis. 2006;56:153-60. (Pubitemid 44488724)
75. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol. 1997;35:830-5. (Pubitemid 27146519)
76. Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet. 1991;337:1378-9.
77. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax. 2003;58:594-7. (Pubitemid 36808130)
78. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009;135:655-61.
79. Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax. 2008;63:154-9. (Pubitemid 351236483)
80. Fujisawa T, Suda T, Matsuda H, Inui N, Nakamura Y, Sato J, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009;14:203-9.
81. Matsumura Y, Ito Y, Iinuma Y, Yasuma K, Yamamoto M, Matsushima A, et al. Quantitative real-time PCR and the (1 → 3)-β-d-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect. 2012;18:591-7.
82. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-β-d-glucan assay for the diagnosis of invasive fungal infections: a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864-70.
83. Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto K, Kawano S, et al. Diagnostic accuracy of serum 1,3-β-d-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7-15.
84. Marty FM, Koo S, Bryar J, Baden LR. (1 → 3) Beta-d-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med. 2007;147:70-2. (Pubitemid 351664641)
85. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131:1173-80. (Pubitemid 46608722)
86. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1 → 3) beta-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128-31.
87. de Boer MG, Gelinck LB, van Zelst BD, van de Sande WW, Willems LN, van Dissel JT, et al. β-d-Glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62:93-100.
88. Koga M, Koibuchi T, Kikuchi T, Nakamura H, Miura T, Iwamoto A, et al. Kinetics of serum β-d-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med. 2011;50:1397-401.
89. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995;108:415-8.
90. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361:1267-8. (Pubitemid 36428582)
91. Kuhlman JE, Kavuru M, Fishman EK, Siegelman SS. Pneumocystis carinii pneumonia: spectrum of parenchymal CT findings. Radiology. 1990;175:711-4. (Pubitemid 20191932)
92. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007;13:1-7. (Pubitemid 46356234)
93. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med. 2010;49:273-81.
94. Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung. 2010;188:159-63.
95. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207.
96. Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41:862-8.
97. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64:1282-90.
98. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301-5. (Pubitemid 39434890)
99. Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J, Masur H, et al. International HIV-associated Opportunistic Pneumonias (IHOP) Study; Lung HIV Study. HIV-associated Pneumocystis pneumonia. Proc Am Thorac Soc. 2011;8:294-300.
100. Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis. 2005;5:101. (Pubitemid 41662731)
101. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-24. (Pubitemid 28223807)
102. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Lee SO, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011;55:4613-8.
103. Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670-2. (Pubitemid 29439970)
104. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 2000;49(RR-10):25-26.
105. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77:299-311.
106. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transpl. 2009;9:S227-33.
107. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc. 1996;71:102-3.
108. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transpl. 2002;17:36-9.
109. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011;13:551-8.
110. Thomas S, Vivancos R, Corless C, Wood G, Beeching NJ, Beadsworth MB. Increasing frequency of Pneumocystis jirovecii pneumonia in renal transplant recipients in the United Kingdom: clonal variability, clusters, and geographic location. Clin Infect Dis. 2011;53:307-8.
111. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41:497-502.
112. Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73:1123-9.
113. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther. 2009;11:253.
114. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:1615-6.
115. Thomas CF, Limper AH. Treatment and prevention of Pneumocystis carinii (P. jirovecii) pneumonia in non-HIV-infected patients. http://www.uptodate.com/ contents/. Accessed 20 Feb 2012.
116. Anand S, Samaniego M, Kaul DR. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis. Transpl Infect Dis. 2011;13:570-4.
117. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.